Regulatory Signal: FDA Final Order — General and Plastic Surgery Devices; Reclassification of Optical Diagnostic Devices for Melanoma Detection | Federal Register, March 25, 2026 | Docket No. 2026-05772
If your organization manufactures, distributes, or is planning to bring to market an optical diagnostic device for melanoma detection or an electrical impedance spectrometer used on skin lesions, a significant regulatory threshold just shifted beneath your feet — and in a favorable direction. The FDA has officially downclassified these device types from Class III to Class II under special controls, replacing the most burdensome premarket approval (PMA) pathway with the more accessible 510(k) premarket notification process.
But "more accessible" does not mean "less rigorous." As I've seen in my work at Certify Consulting across 200+ medical device clients, reclassification events are precisely the moments when manufacturers make costly compliance missteps — either by underestimating new special controls requirements or by failing to act within the required transition windows.
This article breaks down exactly what changed, why it matters, and what your quality management system (QMS) needs to do about it — starting now.
What the FDA Actually Did: The Final Order Explained
On March 25, 2026, the FDA published a final order in the Federal Register reclassifying two postamendments Class III device types into Class II (Special Controls), subject to premarket notification (510(k)):
- Product Code OYD — Optical diagnostic devices for melanoma detection
- Product Code ONV — Electrical impedance spectrometers
Beyond the class change, the FDA is also renaming and codifying these devices under a new, unified classification regulation: "software-aided adjunctive diagnostic devices for use on skin lesions by physicians." This rename reflects the technological reality of how these products work today — most rely on software algorithms, machine learning outputs, or computer-aided detection pipelines layered on top of optical or impedance sensing hardware.
The reclassification is grounded in the FDA's authority under 21 U.S.C. § 360c(e), which allows the agency to reclassify a device when sufficient information exists to establish that special controls, in combination with general controls, can provide reasonable assurance of safety and effectiveness — eliminating the need for a PMA.
This is a meaningful regulatory statement. The FDA is affirming that the body of clinical evidence, post-market surveillance data, and available design controls now support a lower regulatory burden for this device category.
Why This Reclassification Matters: The Stakes Are High
Melanoma is the deadliest form of skin cancer. According to the American Cancer Society, approximately 100,640 new cases of melanoma are projected in the United States in 2024, with an estimated 8,290 deaths. Early, accurate detection is directly tied to survival outcomes — making the devices in this category clinically consequential, not merely commercially interesting.
From a regulatory standpoint, the Class III designation historically meant manufacturers needed to pursue a PMA — a process that typically costs $500,000 to over $1 million and takes an average of 180 days for FDA review after submission, often with multiple rounds of additional information requests. For many smaller innovators, this pathway was a de facto market-entry barrier.
Reclassification to Class II with 510(k) substantially changes that calculus. The standard 510(k) review goal is 90 days, and while De Novo pathways for novel devices have their own timelines, the overall burden is materially reduced. This reclassification opens the door for a broader ecosystem of developers — including digital health startups and AI/ML-driven diagnostic companies — to enter the market with greater speed and at lower cost.
That said, special controls are not optional decorations. They carry binding compliance obligations that must be woven into your QMS, technical file, and 510(k) submission.
The New Classification: "Software-Aided Adjunctive Diagnostic Devices for Use on Skin Lesions by Physicians"
The renaming of this device category is substantively important — not just cosmetic. Here is what the new classification language signals:
| Element | Implication |
|---|---|
| "Software-aided" | Software is a primary, not incidental, component. FDA expects robust software documentation (e.g., IEC 62304 lifecycle compliance, algorithm validation) |
| "Adjunctive" | These devices assist physician decision-making; they do not replace it. Labeling must clearly communicate this scope limitation |
| "Diagnostic" | Clinical performance data (sensitivity, specificity, NPV, PPV) against a validated reference standard (biopsy/histopathology) is required |
| "For use on skin lesions" | Intended use is tightly scoped; off-label use risk must be addressed in your risk management file |
| "By physicians" | User population is defined. Human factors engineering studies must reflect physician-level use scenarios, not lay users |
Understanding what the FDA embedded in this new device name is the first step in building a compliant technical file. Each word carries regulatory weight.
Class III vs. Class II: What Actually Changes for Manufacturers
This comparison is critical for resource planning and QMS updates:
| Requirement | Former Class III (PMA) | New Class II (510(k) + Special Controls) |
|---|---|---|
| Primary premarket pathway | Premarket Approval (PMA) | 510(k) Premarket Notification |
| FDA review target | 180 days (often longer) | 90 days |
| Typical submission cost | $500K–$1M+ | $50K–$200K (est.) |
| Annual reporting | PMA Annual Report required | MDR and standard post-market surveillance |
| Clinical data requirement | Full clinical trials typically required | Bench testing + targeted clinical data per special controls |
| Post-approval studies | Commonly required as PMA conditions | Not standard; may be addressed via special controls |
| Software documentation | Required under PMA | Required under special controls (likely IEC 62304, FDA SaMD guidance) |
| Labeling | PMA-approved labeling | 510(k)-cleared labeling; must reflect adjunctive use |
The key takeaway: Less regulatory burden upfront does not mean less rigor in your design controls, risk management, or clinical evidence package. Special controls define a floor, not a ceiling.
What Are the Special Controls? Breaking Down Compliance Obligations
While the full enumerated list of special controls will be codified in the Code of Federal Regulations under 21 CFR Part 878 (General and Plastic Surgery Devices), FDA's final order establishes the framework. Based on the reclassification order and the FDA's standard approach to software-aided diagnostic devices, manufacturers should anticipate special controls addressing:
1. Performance Testing Requirements
- Analytical and clinical performance data demonstrating diagnostic accuracy against a histopathologically confirmed reference standard
- Minimum thresholds for sensitivity and specificity across relevant skin phototypes, lesion types, and clinical settings
- Subgroup analyses to identify performance disparities across demographic groups (a growing FDA priority under health equity guidance)
2. Software Documentation
- IEC 62304:2006+AMD1:2015 — Software lifecycle processes
- Software description, architecture, and hazard analysis
- Algorithm training and validation datasets: source, size, diversity, and independence of training vs. test sets
- If the device uses machine learning: documentation of model retraining policies, drift monitoring, and any locked vs. adaptive algorithm status per FDA's AI/ML action plan
3. Human Factors and Usability
- Formative and summative usability studies reflecting physician use contexts
- Labeling clarity studies demonstrating that "adjunctive" use limitations are understood by intended users
- Risk analysis for use errors, including overreliance on device output
4. Labeling Requirements
Expect specific required labeling statements, including: - Clear identification of the device as adjunctive only — not a standalone diagnostic - Limitations of use (e.g., specific lesion types, skin phototype validation ranges) - Statement that clinical decision-making rests with the treating physician
5. Post-Market Surveillance
- Complaint handling and adverse event reporting under 21 CFR Part 803 (MDR)
- Post-market clinical follow-up (PMCF) plan addressing real-world performance monitoring
- Potentially a registry commitment or periodic summary reporting, depending on FDA's special controls text
Effective Dates and Compliance Deadlines: A Timeline for Action
The Federal Register publication date of March 25, 2026 starts the compliance clock. Here is what manufacturers need to track:
| Milestone | Date / Timeframe | Action Required |
|---|---|---|
| Final Order Published | March 25, 2026 | Read the full order; begin gap assessment |
| CFR Codification Effective | Typically 30 days post-publication (~April 24, 2026) | New classification regulation becomes enforceable |
| Existing PMA holders | Per FDA transition provision in final order | Review transition provisions; determine if 510(k) submission or exemption applies |
| New market entrants | Immediately upon effective date | Must submit 510(k) with special controls addressed; PMA pathway no longer applicable |
| Labeling updates | Within FDA-specified transition window | Update IFU, product labeling, and marketing materials to reflect new device name and adjunctive use language |
| QMS updates | Continuous; target within 90 days | Update SOPs, risk management files, design history files per new classification |
⚠️ Critical Note for PMA Holders: If you currently hold a PMA for a device falling under OYD or ONV product codes, the final order will include specific transition provisions. You are not automatically converted to Class II. Review the order's transition language carefully — you may need to submit a new 510(k) or comply with a deemed-cleared provision. Failure to act within transition windows is a compliance violation. I strongly recommend engaging regulatory counsel or a qualified consultant immediately.
Practical Compliance Guidance: 7 Steps to Take Right Now
In my experience guiding medical device manufacturers through reclassification events, here are the seven most impactful actions you can take in the next 60–90 days:
Step 1: Conduct a Formal Regulatory Impact Assessment
Map your current technical documentation, design history file (DHF), and 510(k) or PMA submission against the new special controls requirements. Identify every gap. Prioritize by risk to submission readiness.
Step 2: Update Your Risk Management File
Under ISO 14971:2019, your risk management process must reflect the device's current regulatory context and intended use characterization. The "adjunctive diagnostic" framing changes how you characterize hazards related to false negatives, overreliance, and use errors. Update your FMEA and risk/benefit analysis accordingly.
Step 3: Audit Your Software Documentation
If your device includes any software component — and under the new "software-aided" classification, it almost certainly does — your software documentation must align with IEC 62304 and FDA's current SaMD (Software as a Medical Device) guidance. If you use AI/ML algorithms, review FDA's 2021 AI/ML Action Plan and the proposed regulatory framework for predetermined change control plans.
Step 4: Validate Clinical Performance Data Against Special Controls
Your existing clinical data (if any) may not be sufficient to satisfy the new special controls' performance thresholds. Assess whether additional clinical validation studies are needed, and if so, begin protocol development immediately. Clinical studies take time — do not let this be your critical path bottleneck.
Step 5: Revise Labeling and Instructions for Use (IFU)
All labeling must be updated to reflect: - The new device classification name - Adjunctive use limitations - Intended user population (physicians) - Validated use conditions and limitations
Submit labeling to a 510(k) review; do not distribute updated product with new claims before clearance.
Step 6: Update Your ISO 13485:2016 QMS Procedures
Ensure your QMS SOPs — particularly those covering Design and Development (clause 7.3), Risk Management (clause 7.1), Post-Market Surveillance, and Regulatory Requirements tracking (clause 4.1) — reflect the reclassification and new special controls. An auditor reviewing your QMS should be able to trace how the reclassification was identified, assessed, and incorporated into your quality system.
For guidance on building a robust QMS aligned with FDA requirements, see our resource on ISO 13485 design controls and technical documentation.
Step 7: Prepare Your 510(k) Submission Package
Begin assembling your 510(k) submission early. Key components for this device type will include: - Device description and intended use - Predicate device identification (substantial equivalence argument) - Performance testing summary addressing special controls - Software documentation summary - Labeling - Human factors summary
If you do not have an FDA-cleared predicate device identified, you may need to pursue a De Novo classification request instead — a distinct pathway with its own timeline and requirements.
What This Means for the Broader Digital Health and AI Diagnostics Market
This reclassification is part of a larger FDA trend toward enabling innovation in AI-powered diagnostic tools while maintaining appropriate oversight through well-defined special controls. As FDA has consistently stated, the goal is to calibrate regulatory burden to actual risk — and the accumulating evidence base for melanoma detection technology now supports that recalibration.
For manufacturers operating at the intersection of software, artificial intelligence, and dermatological diagnostics, this is a genuine market-entry opportunity. The 510(k) pathway, when navigated with a complete and well-organized submission, can result in clearance decisions well within the 90-day review goal.
However — and I cannot emphasize this enough — the quality and completeness of your special controls documentation will determine your success. FDA reviewers will scrutinize algorithm performance data, training dataset diversity, and labeling clarity with significant rigor. A poorly prepared 510(k) for a device in this category is not just a delay; it can trigger an additional information (AI) request cycle that adds months to your timeline.
For a deeper look at how to structure your technical documentation for FDA submissions, review our guide on preparing ISO 13485-compliant technical files for 510(k) submissions.
Citation-Ready Summary: Key Facts for Reference
The following statements summarize the essential regulatory facts from this reclassification:
FDA's March 25, 2026 final order reclassifies optical diagnostic devices for melanoma detection (product code OYD) and electrical impedance spectrometers (product code ONV) from Class III to Class II (Special Controls), subject to 510(k) premarket notification, under the new unified classification "software-aided adjunctive diagnostic devices for use on skin lesions by physicians."
Under the reclassification, manufacturers of OYD and ONV devices are no longer required to submit a Premarket Approval (PMA) application; instead, a 510(k) premarket notification demonstrating substantial equivalence and compliance with applicable special controls is required for market entry.
The reclassification is codified under 21 CFR Part 878 (General and Plastic Surgery Devices) and takes effect approximately 30 days after the March 25, 2026 Federal Register publication date.
About the Author
Jared Clark, JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, RAC is the Principal Consultant at Certify Consulting, where he has guided 200+ medical device manufacturers through FDA submissions, ISO 13485 certification, and regulatory reclassification events — with a 100% first-time audit pass rate over 8+ years of practice. Jared specializes in QMS strategy, technical documentation, and FDA regulatory compliance for medical device companies from startup to enterprise scale.
Last updated: 2026-03-27
Source: FDA Federal Register Final Order, Docket No. 2026-05772, March 25, 2026
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.